WO2018021874A1 - Serviette hygiénique fonctionnelle - Google Patents

Serviette hygiénique fonctionnelle Download PDF

Info

Publication number
WO2018021874A1
WO2018021874A1 PCT/KR2017/008163 KR2017008163W WO2018021874A1 WO 2018021874 A1 WO2018021874 A1 WO 2018021874A1 KR 2017008163 W KR2017008163 W KR 2017008163W WO 2018021874 A1 WO2018021874 A1 WO 2018021874A1
Authority
WO
WIPO (PCT)
Prior art keywords
culture
accession
nite
sanitary napkin
lactobacillus plantarum
Prior art date
Application number
PCT/KR2017/008163
Other languages
English (en)
Korean (ko)
Inventor
김기태
Original Assignee
바이오제닉스코리아 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오제닉스코리아 주식회사 filed Critical 바이오제닉스코리아 주식회사
Publication of WO2018021874A1 publication Critical patent/WO2018021874A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A61F13/45—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the shape
    • A61F13/47—Sanitary towels, incontinence pads or napkins
    • A61F13/472—Sanitary towels, incontinence pads or napkins specially adapted for female use
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A61F13/84—Accessories, not otherwise provided for, for absorbent pads
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A61F13/84—Accessories, not otherwise provided for, for absorbent pads
    • A61F13/8405—Additives, e.g. for odour, disinfectant or pH control
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/36—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A61F2013/16—Sanitary towels; Means for supporting or fastening them
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A61L2300/406—Antibiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs

Definitions

  • the present invention relates to a functional sanitary napkin, and more particularly, to a functional sanitary napkin having antibacterial, anti-inflammatory and anti-allergic properties, which can prevent infection, skin irritation, and eczema by pathogens.
  • the endometrium of a woman of childbearing age is periodically proliferated by hormones to prepare for implantation of the embryo. If the pregnancy does not occur, the endometrium is spontaneously dropped and this phenomenon is called menstruation or menstruation.
  • Fertility refers to the period during which the egg can ovulate and become pregnant. It refers to the period from the beginning of menarche to menopause. The average menopause age is about 13 years old and the average menopause age is about 50 years old. Menstrual cycles can be divided into follicular and luteal phases, and ovulation occurs during the transition from follicular phases to luteal phases.
  • the sanitary napkin is used to prevent leakage of menstrual blood and secretion during the menstrual period, as shown in Figure 1, the sanitary napkin is generally to prevent the leakage of the internal sheet 100, such as menstrual blood, and menstrual blood
  • the outer sheet 300 and the absorbent member 200 positioned between the inner sheet 100 and the outer sheet 300 to absorb the menstrual blood, etc., and to absorb the menstrual blood.
  • the outer sheet 300 may be provided with an adhesive means such as an adhesive material.
  • sanitary napkins may cause skin irritation, skin eczema, and skin irritation due to secretions such as menstrual blood, and during menstruation, mental and physical resistance is weakened. Therefore, human infections such as skin infections and vaginal infections are caused by bacterial growth such as pathogens. May cause problems.
  • the present invention confirms that lactic acid bacteria cultures such as Lactobacillus plantarum nF1 disclosed in Korean Patent Registration No. 10-1583018 and Korean Patent Application Publication No. 2014-0140387 have anti-allergic and anti-inflammatory activity as well as antibacterial activity.
  • a functional sanitary napkin is disclosed that can prevent human infection by bacteria such as pathogens and prevent skin irritation.
  • An object of the present invention is to provide a functional sanitary napkin that can prevent infection and skin irritation caused by pathogens.
  • the functional sanitary napkin of the present invention comprises (i) an inner sheet and an outer sheet, and (ii) an absorbent member interposed therebetween, wherein the inner sheet and / or absorbent member is Lactobacillus plantarum. It is characterized by impregnating a lactic acid bacteria culture such as nF1 or a solution containing the same.
  • the functional sanitary napkin of the present invention exhibits anti-inflammatory, anti-allergic, as well as antibacterial, Due to such antimicrobial properties, it has the effect of preventing human infection from bacteria such as pathogens, and also has the effect of preventing skin irritation, skin eczema, and skin inflammation caused by secretions such as menstrual blood.
  • lactic acid bacteria cultures such as Lactobacillus plantarum nF1, Bacillus subtilis , Staphylococcus aureus (except for some microorganisms of some cultures) Staphylococcus aureus ), Staphylococcus mutans ( Strptococcus) mutans ), Escherichia coli ) and Gardnerella vaginalis , which have an overall antimicrobial activity and produce nitric oxide (NO) in macrophages, a major cell in the inflammatory response stimulated with the inflammatory substance lipopolysacharide (LPS).
  • NO nitric oxide
  • LPS lipopolysacharide
  • rat cell line RBL-2H3 rat basophilic leukemia
  • IgE and antigen DNP-BSA
  • the gardnerella pannalis is an anaerobic bacterium known as a major causative agent of bacterial vaginosis found in more than 98% of women with bacterial vaginosis (Korean Journal of Obstetrics and Gynecology 36 (6): 837-46, 1993). Bacterial vaginosis caused by is caused to increase the pH in the vagina to 5.0 or more, exhibits peculiar odors, pruritus and other symptoms, and is characterized by increased vaginal discharge (Am J Obstet Gynecol. 158 (4): 819-). 28, 1988).
  • mast cells which are the major mediators of allergic reactions, contain beta-hexosaminidase in addition to histamine, and beta-hexosaminidase is released together with histamine when mast cells degranulate.
  • Beta-hexosaminidase is known as an indicator for assessing degranulation inhibitory activity, antihistamine activity and anti-allergic activity of mast cells (Immunol., 123: 1445-1450, 1970); J Korean Soc Appl Biol Chem. 48 (4): 315-321, 2005).
  • lactic acid bacteria cultures such as Lactobacillus plantarum nF1 prevent bacterial vaginosis caused by infections such as Gardnerella pannalis through antibacterial activity, anti-inflammatory activity and anti-allergic activity. It can be said that it can alleviate skin inflammation.
  • lactic acid bacteria refers to Lactobacillus plantarum nF1 (Accession No. NITE P-1462), Lactobacillus plantarum SNK12 (Accession No .: NITE P-1445), Lactobacillus plantarum KH3 (Accession No. NITE AP) -1476), Enterococcus faecalis KH2 (Accession No. NITE P-1444), and / or Lactobacillus brevis (Accession No. FERP BP-4693) ("Labre”), which are lactobacillus products manufactured by an independent Japanese corporation. It is a microorganism entrusted to the National Institute of Technology and Evaluation (NITE; International Patent Organism Depositary, IPOD) of the Evaluation Technology Infrastructure Organization. See 2014-0140387. These patent documents are all considered part of this specification.
  • lactic acid bacteria culture is obtained by inoculating and culturing lactic acid bacteria with a suitable medium in which lactic acid bacteria can grow, such as MRS Broth.
  • a suitable medium in which lactic acid bacteria can grow such as MRS Broth.
  • the culture itself and its culture are concentrated under reduced pressure and / or lyophilized.
  • the culture itself or the processed product thereof having a lower alcohol having 1 to 4 carbon atoms such as water, methanol, ethanol, butanol, methylene chloride, ethylene, acetone, hexane, ether, chloroform, ethyl acetate Suspensions or solutions suspended or dissolved in butyl acetate, N, N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), 1,3-butylene glycol, propylene glycol or a mixed solvent thereof, the culture Meaning extracting itself or its processed product with the solvents listed above, and processing the extract into liquid or powder form by concentration under reduced pressure and / or lyophilization. .
  • a lower alcohol having 1 to 4 carbon atoms such as water, methanol, ethanol, butanol, methylene chloride, ethylene, acetone, hexane, ether, chloroform, ethyl acetate
  • dispersion medium or the solvent after the impregnation in a manner known in the art such as a hot air drying method.
  • a hot air drying method In order to stabilize the impregnation of the lactic acid bacteria culture and to prevent the dispersion medium or the solvent may be toxic to the human body such as skin irritation. For this reason, preferred dispersion mediums or solvents are water, ethanol or a mixed solvent thereof.
  • the functional sanitary napkin of the present invention may further include an auxiliary absorbing member, and when the auxiliary absorbing member is further included, an end portion may be further formed in the endothelial sheet so that the auxiliary absorbing member may be detachably inserted.
  • the functional sanitary napkin of the present invention is an inner sheet, an absorbent member, an outer sheet, and an optional absorbent member which is an optional absorbent member, which is a component of a conventional sanitary napkin, and their materials and configurations are known in the art, and related details are as follows. See embodiments of.
  • a functional sanitary napkin impregnated with a lactic acid bacteria culture such as Lactobacillus plantarum nF1 exhibiting antibacterial activity, anti-inflammatory activity, anti-allergic activity and the like can be provided.
  • the functional sanitary napkin of the present invention is impregnated with a lactic acid bacteria culture such as Lactobacillus plantarum nF1, which exhibits antimicrobial activity, anti-inflammatory activity, anti-allergic activity, etc., and thus has an effect of preventing human infection from bacteria such as pathogens. It has the effect of preventing skin irritation, skin eczema, and skin inflammation caused by secretions such as menstrual blood.
  • a lactic acid bacteria culture such as Lactobacillus plantarum nF1
  • Lactobacillus plantarum nF1 which exhibits antimicrobial activity, anti-inflammatory activity, anti-allergic activity, etc.
  • FIG. 1 is a perspective view of a sanitary napkin according to a preferred embodiment of the present invention.
  • FIG. 2 is an exploded perspective view of the sanitary napkin according to the preferred embodiment of the present invention.
  • FIG. 3 is a perspective view of a sanitary napkin according to another preferred embodiment of the present invention.
  • FIG. 1 is a perspective view of a sanitary napkin according to a preferred embodiment of the present invention
  • Figure 2 is an exploded perspective view of the sanitary napkin according to a preferred embodiment of the present invention.
  • the antibacterial sanitary napkin is largely composed of an inner sheet 100 and an outer sheet 300 and an absorbing member 200 disposed therebetween.
  • the inner sheet 100 has a material and structure through which secretion, such as menstrual blood, can pass, and may be specifically composed of one or more layers of fabrics or nonwoven fabrics.
  • the fibers constituting the woven or nonwoven fabric can be used both synthetic fibers and natural fibers without particular limitation, if synthetic fibers, nylon, polyvinyl alcohol (PVA) fibers, polyester fibers, polyacrylic fibers, polyamide fibers, polyurethane Fibers, polyacrylonitrile fibers, polypropylene fibers, polyethylene fibers and the like can all be used without limitation, and if natural fibers, cotton fibers, seed fibers such as Coier, leaf vein fibers such as manila hemp and sisal hemp, flax , Bast fibers such as ramie grass, hemp, wool fibers such as wool, goat wool, silk fibers such as gaze dog, and night sleep dog can be used without limitation.
  • a fabric made of natural fibers such as cotton fabrics.
  • the inner sheet 100 is a member in contact with the human body may be caused skin irritation, skin eczema, skin inflammation, etc. by secretions such as menstrual blood absorbed in the inner sheet 100 or penetrating the inner sheet 100, including pathogens Since various bacteria can proliferate, in order to prevent such skin irritation and suppress the growth of various bacteria, Lactobacillus has been confirmed antimicrobial activity, anti-inflammatory activity, anti-allergic activity, etc., as confirmed in the experimental example below Lactobacillus cultures such as plantarum nF1, its extracts, its concentrates, its dilutions, or its suspensions or solutions using a dispersion medium or a solvent as water or ethanol are impregnated into the inner sheet 100 for antibacterial function, You can have anti-inflammatory activity, anti-allergy, etc.
  • the impregnation may be made by immersing the inner sheet 100 in a diluent of a lactic acid bacterium culture such as Lactobacillus plantarum nF1 at room temperature, preferably for at least 12 hours, more preferably at least 24 hours.
  • a lactic acid bacterium culture such as Lactobacillus plantarum nF1
  • the lactic acid bacteria cultures such as Lactobacillus plantarum nF1 which are impregnated, are stabilized and hot air dried at a temperature ranging from 40 ° C. to 50 ° C., for example, to remove solvents that may cause irritation or toxicity to the skin. It may be desirable to.
  • Such natural materials include plant extracts having anti-inflammatory activity, anti-allergic activity, or both, specifically, Styrax japonica extract, Chloranthus japonicus ) extract, Podocarpus macrophyllus extract, Distylium racemosom extract, Rhododendron mucronulatum , Empetrum nigrum extract, Marsilea quadrifolia extract, Potentilla discolor extract, Gleichenia japonica extract, Cimicifuga acerina extract, Citrus sunki rind extract, Sceptridium ternatum extract and Korthalsella japonica extract are among such plant extracts.
  • endothelial sheet When the extract is impregnated, endothelial sheet by immersing the endothelial sheet 100 in these natural product extracts at a constant time, such as 12 hours or 24 hours or more at room temperature, using an extract in the extract state with or without filtration.
  • Functionality such as skin irritation relief can be imparted to (100).
  • the extraction solvent which may have skin irritation may be a solvent remaining in the endothelial sheet 100 when impregnated, and the residual solvent may cause skin irritation, so that the impregnated inner sheet 100 may be hot air dried.
  • Drying is carried out in a manner known in the art to remove residual solvents, or when using an extract obtained with an extraction solvent other than water and ethanol, it is concentrated in the art after extraction, freeze drying, vacuum drying, hot air drying, spray drying, etc. It is also possible to avoid the skin irritation problem caused by the extraction solvent by removing the extraction solvent in a manner known in the present invention to obtain a powdered extract and dissolving the powdered extract in water or ethanol, especially ethanol.
  • the absorbent member 200 is to absorb secretions such as menstrual blood, so that the absorbency and water retention should be excellent, so that the absorbent member 200 may consider cotton fiber or wool, goat's wool, etc. It can be made of the hair wool fiber, etc. in the form of cotton and the composition of the nonwoven fabric and the like.
  • the content may be a polymer absorbent such as sodium polyacrylate, which has been conventionally used in sanitary napkins.
  • Sodium polyacrylate is a material known in the art to have an absorption ability to absorb about 200 times its weight.
  • the absorbing member 200 is a member for absorbing secretions such as menstrual blood, bacteria such as pathogens may proliferate. Therefore, in order to suppress this, it is preferable to impregnate the culture of lactic acid bacteria such as Lactobacillus plantarum nF1, such as the antibacterial activity is confirmed, such as the inner sheet 100 to have an antibacterial function.
  • lactic acid bacteria such as Lactobacillus plantarum nF1
  • the antibacterial activity is confirmed, such as the inner sheet 100 to have an antibacterial function.
  • the outer sheet 300 is located on the outside of the absorbent member 200. Since the outer sheet 300 is a member in contact with the underwear without touching the skin, it should be able to prevent the leakage of secretion such as menstrual blood. It is made of a waterproof material such as polyethylene film. In addition, the outer surface of the outer sheet 300 can be attached to and fixed to the underwear by forming an adhesive member with an adhesive and release paper.
  • the adsorption member 200 is finally placed between the inner sheet 100 and the outer sheet 300, and the periphery of the inner sheet 100 and the outer sheet 300 is stitched, ultrasonically fused or heated. It is made by bonding by fusion.
  • the functional sanitary napkin of the present invention may further comprise an auxiliary adsorption member 400 for further use in the case of a large amount of secretion, such as menstrual blood, depending on the woman as shown in FIG.
  • the auxiliary adsorption member 400 may be made of cotton fibers, wool fibers such as wool, goat wool, or the like in the form of cotton, or a polymer absorbent such as sodium polyacrylate.
  • the outer shell may be made of a nonwoven fabric or the like.
  • the inner sheet 100 may be inserted to detach the auxiliary adsorption member 100 by forming a cutout 101.
  • auxiliary adsorption member 400 it may be preferable to impregnate the lactic acid bacteria culture such as Lactobacillus plantarum nF1 so that the auxiliary adsorption member 400 also has antibacterial properties.
  • the functional sanitary napkin of the present invention has been described based on the inner sheet 100, the absorbent member 200, and the outer sheet 300, which are basic components, but the functional sanitary napkin of the present invention is the inner sheet 100 and / or absorbent.
  • the member 200 is impregnated with a culture of lactic acid bacteria such as Lactobacillus plantarum nF1 to have antimicrobial activity, anti-inflammatory activity, anti-allergy, and the like. It is to be understood that added and modified sanitary napkins are also included in the scope of the present invention.
  • Lactobacillus was inoculated at MRS (DeMan, Rogosa, and Sharpe) broth (Difco Lactobacilli MRS Broth, Japan Becton, Dickinson & Co.) at an initial cell concentration of 1 ⁇ 10 4 cfu / mL, and Lactobacillus plantarum nF1 (Accession No. NITE P-1462) ("nF1"), Lactobacillus plantarum SNK12 (Accession Number: NITE P-1445) (“SNK12”), Lactobacillus plantarum KH3 (Accession Number NITE AP-1476) ("KH3" ) At 32 ° C., 37 ° C.
  • KH2 Enterococcus faecalis KH2 (Accession No. NITE P-1444) (“KH2”), and 31 to 32 for Lactobacillus brevis (Accession No. FERP BP-4693) (“Labre”).
  • C. Lactococcus lactis subspecies Cremoris CF4 (Accession No. FERM P-20848) (“CF4”) was incubated at 30 ° C. for 2 days.
  • the culture was sterilized at 121 ° C. for 20 minutes using a sterilizer, concentrated under reduced pressure and lyophilized, and used for experiments while refrigerated.
  • Antimicrobial activity was measured by plate medium diffusion method (Food. Chem. Toxicol. 40 (4): 535-543, 2002).
  • the disk to be used for the experiment was dissolved in ethanol at a concentration of 1 mg / ml of the sample (culture of ⁇ Experimental Example 1-1>), and then slowly absorbed the sample solution into the disk (Whatman No. 5), and then completely removed the solvent.
  • the prepared disk was adhered to the plate medium plated with each test bacteria and incubated at the incubation temperature of the following [Table 1], and then the size (mm) of growth zones (clear zone) formed around the disk was measured. The results are shown in [Table 2].
  • Anti-inflammatory activity was evaluated using a cell model in which RAW264.7 cells, a mouse macrophage line, were stimulated with Lipopolysacharide (LPS). Specifically, the mouse macrophage cells were dispensed in a 48 well plate with a cell number of 5 ⁇ 10 4 cells / well and incubated for 24 hours at 37 ° C. and 5% CO 2 . 100 ⁇ g / ml sample and 1 ⁇ g / ml LPS were co-treated and incubated for 24 hours.
  • LPS Lipopolysacharide
  • Cell viability was measured by the MTT method. Specifically, the remaining medium in the 48 well plate was removed, and 100 ⁇ l of serum free medium containing 10% of 5 mg / ml MTT solution was added to each well in 37 ° C. and 5% CO 2 incubator, followed by reaction for 2 hours. Removed and dissolved DMSO in 100 ⁇ l / well for 15 minutes in the shaker and measured the absorbance at 540nm using ELlSA reader to determine the cell viability. The results are shown in Table 3 together.
  • Anti-allergic activity was assessed by ⁇ -hexosaminidase assay.
  • a rat basophilic leukemia cell line RBL-2H3 cell line was dispensed into 2 wells at 24 ⁇ plates at 2 ⁇ 10 5 cells / well and treated with 0.5 ⁇ g / ml mouse monoclonal IgE at 37 ° C., 5%. Cells were sensitized by incubating overnight in CO 2 conditions.
  • the sensitized cells were washed twice with siraganian buffer (25 mM PIPES, 119 mM NaCl, 5 mM KCl, 0.4 mM MgCl 2 , 40 mM NaOH, pH 7.2) and 160 ⁇ l PIPES buffer (25 mM PIPES, 119 mM NaCl, 5 mM KCl, 1 mM CaCl 2 , 0.4 mM MgCl 2 , 40 mM NaOH, 5.6 mM glucose, 0.1% BSA) was added and incubated at 37 ° C. for 10 minutes.
  • siraganian buffer 25 mM PIPES, 119 mM NaCl, 5 mM KCl, 0.4 mM MgCl 2 , 40 mM NaOH, 5.6 mM glucose, 0.1% BSA
  • DNP-HSA Dinitrophenyl-Human Serum Albumin, 1 ⁇ g / ml
  • 20 ⁇ l of the supernatant of the reactants was put into a 96 well plate, and 20 ⁇ m of substrate 1 mM P-nitrophenyl-acetyl- ⁇ -D-glucosamide was added and reacted at 37 ° C. for 1 hour.
  • a stop solution (0.1 M NaHCO 3 , 0.1 M Na 2 CO 3 ) was added thereto, and the reaction was terminated.
  • the absorbance was measured using an ELISA reader at a wavelength of 405 nm. The results are shown in [Table 4] as a percentage compared to the sample untreated group.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Materials Engineering (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Absorbent Articles And Supports Therefor (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne une serviette hygiénique fonctionnelle qui est imprégnée d'une culture de lactobacillale (de bactéries d'acide lactique), telles que Lactobacillus plantarum nF1, présentant des activités antibactériennes, anti-inflammatoires et anti-allergiques, ce qui permet d'empêcher des agents pathogènes tels que les bactéries d'infecter le corps humain et les sécrétions telles que le sang menstruel, de provoquer une irritation de la peau, un eczéma de la peau et une inflammation de la peau.
PCT/KR2017/008163 2016-07-29 2017-07-28 Serviette hygiénique fonctionnelle WO2018021874A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2016-0096967 2016-07-29
KR20160096967 2016-07-29

Publications (1)

Publication Number Publication Date
WO2018021874A1 true WO2018021874A1 (fr) 2018-02-01

Family

ID=61017262

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2017/008163 WO2018021874A1 (fr) 2016-07-29 2017-07-28 Serviette hygiénique fonctionnelle

Country Status (2)

Country Link
KR (1) KR102087051B1 (fr)
WO (1) WO2018021874A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102111295B1 (ko) 2018-02-05 2020-05-15 주식회사 만도 리던던트 구조 기반의 차량 제어 장치 및 방법

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000061201A1 (fr) * 1999-04-14 2000-10-19 Ganeden Biotech, Inc. Procedes visant a inhiber des infections microbiennes associees a des produits hygieniques
KR20040101335A (ko) * 2002-03-21 2004-12-02 비포단 에이/에스 락토바실러스 균주
KR20110010867A (ko) * 2009-07-27 2011-02-08 이성기 생리대
KR20140140387A (ko) * 2013-05-29 2014-12-09 바이오제닉스코리아 주식회사 나노형 김치 유산균
US20150209468A1 (en) * 2014-01-24 2015-07-30 The Procter & Gamble Company Hygiene article containing microorganism

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR940001575B1 (ko) * 1991-12-24 1994-02-25 주식회사 럭키 락토페린을 이용한 일회용 흡수제품
SE9703669D0 (sv) * 1997-10-08 1997-10-08 Moelnlycke Ab Alster och beredning innefattande mjölksyrabakterier
SE519648C2 (sv) * 1998-03-06 2003-03-25 Essum Ab Ny stam av Lactobacillus plantarum
SE528382C2 (sv) * 2004-10-05 2006-10-31 Probi Ab Probiotiska lactobacillusstammar för förbättrad vaginal hälsa

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000061201A1 (fr) * 1999-04-14 2000-10-19 Ganeden Biotech, Inc. Procedes visant a inhiber des infections microbiennes associees a des produits hygieniques
KR20040101335A (ko) * 2002-03-21 2004-12-02 비포단 에이/에스 락토바실러스 균주
KR20110010867A (ko) * 2009-07-27 2011-02-08 이성기 생리대
KR20140140387A (ko) * 2013-05-29 2014-12-09 바이오제닉스코리아 주식회사 나노형 김치 유산균
US20150209468A1 (en) * 2014-01-24 2015-07-30 The Procter & Gamble Company Hygiene article containing microorganism

Also Published As

Publication number Publication date
KR102087051B1 (ko) 2020-03-10
KR20180013793A (ko) 2018-02-07

Similar Documents

Publication Publication Date Title
KR102258914B1 (ko) 항균 마스크
RU2212902C2 (ru) Продукт и препарат, содержащий молочно-кислые бактерии
AU780367B2 (en) Methods for inhibiting microbial infections associated with sanitary products
EP2081606B1 (fr) Article d'hygiène contenant une composition anti-microbienne
DE69919518T2 (de) Lactobacillus-stamm
CN101678147A (zh) 亲水性载体中含乳酸杆菌的卫生用品
CN104382685B (zh) 一种人体阴道微生态制剂-益生菌避孕套的制备方法
WO2018021874A1 (fr) Serviette hygiénique fonctionnelle
US20100104615A1 (en) Absorbent article comprising lactic acid producing bacteria
CN110680855A (zh) 一种含有益生菌和中药组合物的阴道膨胀栓及其制备方法
CN107937324A (zh) 一株卷曲乳杆菌及其应用
EP1689452B1 (fr) Article absorbant contenant un agent de soins de la peau
Demirezen et al. Cytologic findings in pap smears with Actinomyces-like organisms
CN110547915A (zh) 应用益生菌的卫生棉制品及其制备方法
CN112175867B (zh) 一种基于灭活乳酸菌的功能性无纺布
RU2183963C2 (ru) Мазь "эмулакт" для лечения и профилактики инфекционно-воспалительных гинекологических заболеваний и дисбактериозов
MXPA00003411A (en) Product and preparation containing lactic acid bacteria
Sasso et al. ADHESION OF PROBIOTIC LACTOBACILLI TO HUMAN VAGINAL CELLS IN PRESENCE OF THYMOL AND EUGENOL.
EP3319650A1 (fr) Nouvel article d'hygiène
WO2011003370A2 (fr) Inhibition d’exoprotéines au moyen de bactéries du genre lactobacillus
MXPA00008161A (en) New agent

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17834815

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17834815

Country of ref document: EP

Kind code of ref document: A1